Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma

Cancer Science

Volumn 97, Issue 10, 2006, Pages 1115-1124

  Nozawa, Hiroshi ^a   Tadakuma, Takushi ^a   Ono, Takeshi ^a   Sato, Masaki ^a   Hiroi, Sadayuki ^a   Masumoto, Kazuma ^a   Sato, Yasunori ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATELOCOLLAGEN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FEASIBILITY STUDY; FEMALE; GENE TARGETING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748329381     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00287.x     Document Type: Article

References (57)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
2. Hunter DH, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005; 5: 127-35.
3. Xi S, Grandis JR. Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res 2003; 82: 11-16.
4. Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol 2002; 14: 334-42.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
6. Davies DE, Chamberlin SG. Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem Pharmacol 1996; 51: 1101-10.
7. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996; 7: 133-41.
8. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-84.
9. Ishitoya J, Toriyama M, Oguchi N et al. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br J Cancer 1989; 59: 559-62.
10. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II. Correlations with proliferation and angiogenesis. J Pathol 1998; 184: 53-7.
11. Radinsky R, Risin S, Fan Z et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1: 19-31.
12. Nagane M, Coufal F, Lin H et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996; 56: 5079-86.
13. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl. 4): S9-15.
14. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003; 25: 67-73.
15. Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann Oncol 2000; 11 (Suppl. 3): 187-90.
16. Garber K. Tyrosine kinase inhibitor research presses on despite halted clinical trial. J Natl Cancer Inst 2000; 92: 967-9.
17. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3: 737-47.
18. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.
19. Wang YH, Liu S, Zhang G et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005; 7: R220-8.
20. Leng Q, Mixson AJ. Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo. Cancer Gene Ther 2005; 12: 682-90.
21. Futami T, Miyagishi M, Seki M, Taira K. Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2. Nucl Acids Res Suppl 2002; 2: 251-2.
22. Bertrand JR, Pottier M, Vekris A et al. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002; 296: 1000-4.
23. Aoki Y, Cioca DP, Oidaira H, Kamiya J, Kiyosawa K. RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol 2003; 30: 96-102.
24. Ochiya T, Takahama Y, Nagahara S et al. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: The Minipellet. Nat Med 1999; 5: 707-10.
25. He Y, Zeng Q, Drenning SD et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998; 90: 1080-7.
26. Kim DH, Longo M, Han Y, Lundberg P, Cantin E, Rossi JJ. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004; 22: 321-5.
27. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834-9.
28. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34: 263-4.
29. Tsui P, Rubenstein M, Guinan P. siRNA is not more effective than a first generation antisense oligonucleotide when directed against EGFR in the treatment of PC-3 prostate cancer. In Vivo 2005; 19: 653-6.
30. Bernstein E, Denli AM, Hannon GJ. The rest is silence. RNA 2001; 7: 1509-21.
31. Tuschl T. RNA interference and small interfering RNAs. CHEMBIOCHEM 2001; 2: 239-45.
32. Niwa H, Wentzel AL, Li M, Gooding WE, Lui VW, Grandis JR. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 2003; 9: 5028-35.
33. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-92.
34. Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000; 89: 74-82.
35. Ciardiello F, Caputo R, Troiani T et al. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 2001; 93: 172-8.
36. Grandis JR, Chakraborty A, Melhem MF, Zeng Q, Tweardy DJ. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 1997; 15: 409-16.
37. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-7.
38. Yoo GH, Piechocki MP, Ensley JF et al. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and powerblot. Clin Cancer Res 2002; 8: 3910-21.
39. Kikuchi T, Daigo Y, Katagiri T et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003; 22: 2192-205.
40. Reed JC, Miyashita T, Takayama S et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60: 23-32.
41. Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Res 2003; 63: 1-5.
42. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166-74.
43. Chinnaiyan P, Huang S, Vallabhaneni G et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328-35.
44. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-65.
45. Holsinger FC, Doan DD, Jasser SA et al. Epidermal growth factor receptor blockade potentiates apoptosis mediated by paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 2003; 9: 3183-9.
46. Bruns CJ, Solorzano CC, Harbison MT et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60: 2926-35.
47. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994-1003.
48. Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5: 257-64.
49. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am J Pathol 1997; 151: 1523-30.
50. Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces angiogenic effect through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-60.
51. Stenzel KH, Miyata T, Rubin AL. Collagen as a biomaterial. Ann Rev Biophys Bioeng 1974; 3: 231-53.
52. Ochiya T, Nagahara S, Sano A, Itoh H, Terada M. Biomaterials for gene delivery: Atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther 2001; 1: 31-52.
53. Takei Y, Kadomatsu K, Matsuo S et al. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 2001; 61: 8486-91.
54. Hirai K, Sasaki H, Sakamoto H et al. Antisense oligodeoxynucleotide against HST-1/FGF-4 suppresses tumorigenicity of an orthotopic model for human germ cell tumor in nude mice. J Gene Med 2003; 5: 951-7.
55. Hanai K, Kurokawa T, Minakuchi Y et al. Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease. Hum Gene Ther 2004; 15: 263-72.
56. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365-70.
57. Takeshita F, Minakuchi Y, Nagahara S et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12 177-82.